BioSpace News Archive

Alimera Sciences, Inc. announced that post-hoc analyses from the PALADIN Phase 4 Safety Study demonstrate that median treatment frequency in diabetic macular edema patients treated with the ILUVIEN® 0.19 mg was lower than from patients on other regimens.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces that two abstracts detailing the Company’s RAS-Targeted platform have been accepted to be presented as posters at the National Cancer Institute-sponsored Fourth RAS Initiative Symposium to be held October 17-19, 2022 at The Advanced Technology Research Facility of the National Cancer Institute in Frederick, Maryland.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, announces the expansion of its commercial leadership team with two strategic hires: Brian Collins is joining as Global Vice President of Marketing and Professional Education and Shawn Gabriel as Vice President of Sales, North America.

Bayer, one of the country’s leading life-sciences companies, announced that William Dodero, its current Vice President and Global Head of Litigation, will become the company’s new U.S. General Counsel and Senior Vice President, as well as a member of the U.S. Country Leadership Team.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced two poster presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Meeting in Boston, MA, from November 10-12, 2022.

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced it has dosed its first patient with PLG0206 in the LOGIC-1 trial for the treatment of periprosthetic joint infections (PJI) occurring after a total knee arthroplasty (TKA).

Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), today announced the approval of Cationorm® Plus by Health Canada.

Galapagos NV (Euronext & NASDAQ: GLPG) will present data at the United European Gastroenterology(UEG)Week2022,taking place from8-11 October 2022. Several Galapagos driven presentationswill be showcased, including new post hoc analyses of the SELECTION study, which investigated the safety and efficacy of Jyseleca®(filgotinib).

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022.

Mersana Therapeutics, Inc. (NASDAQ: MRSN) today announced the completion of patient enrollment in UPLIFT, the company’s single-arm registrational trial of UpRi in platinum-resistant ovarian cancer.